Anika Therapeutics Inc Revenue Growth Rates (ANIK), Current and Historic Growth - CSIMarket
CSIMarket
 


Anika Therapeutics Inc   (NASDAQ: ANIK)
 

ANIK's Revenue Growth by Quarter and Year

Anika Therapeutics Inc 's Revenue results by quarter and year




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ANIK/growth
https://api.csimarket.com/api/v1/companies/ANIK/fundamentals
https://api.csimarket.com/api/v1/companies/ANIK/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
ANIK Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 30.59
2nd Quarter June 32.61
1st Quarter March 29.00
FY 92.20

ANIKs Annual Revenue
Anika Therapeutics Inc 's Revenue in the fiscal year 2025 $ 112.81 millions
Anika Therapeutics Inc 's Revenue in the fiscal year 2024 $ 119.00 millions
Anika Therapeutics Inc 's Revenue in the fiscal year 2023 $ 166.09 millions
Anika Therapeutics Inc 's Revenue in the fiscal year 2022 $ 156.24 millions
Anika Therapeutics Inc 's Revenue in the fiscal year 2021 $ 147.79 millions




ANIK Revenue third quarter 2026 Y/Y Growth Comment
Anika Therapeutics Inc achieved in the third quarter 2026, above Company average Revenue increase of 10.93% year on year, to $ 30.59 millions.

Looking into third quarter 2026 results within Medical Equipment & Supplies industry 64 other companies have achieved higher Revenue growth. While Anika Therapeutics Inc ' s Revenue growth of 10.93% ranks overall at the positon no. 1072 in the third quarter 2026.




ANIK Revenue ( Y/Y Growth %) 2026
FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 10.93 %
2nd Quarter June 19.19 %
1st Quarter March 12.93 %
FY   -

Financial Statements
Anika Therapeutics Inc 's third quarter 2026 Revenue $ 30.59 millions ANIK's Income Statement
Anika Therapeutics Inc 's third quarter 2025 Revenue $ 27.58 millions Quarterly ANIK's Income Statement


ANIK Revenue (Quarter on Quarter Growth %)

2026
FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -6.18 %
2nd Quarter June 12.45 %
1st Quarter March -9.88 %
FY (Year on Year)   -




Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #65
Healthcare Sector #212
Overall #1072

Revenue Y/Y Growth Statistics
High Average Low
123.06 % 8.19 % -54.37 %
(Dec 31 2014)   (Sep 30 2025)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #65
Healthcare Sector #212
Overall #1072
Revenue Y/Y Growth Statistics
High Average Low
123.06 % 8.19 % -54.37 %
(Dec 31 2014)   (Sep 30 2025)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Anika Therapeutics Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
60.04 % 4.39 % -33.26 %
(Mar 31 2014)  


ANIK's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Anika Therapeutics Inc disclosed decline in Revenue from the second quarter by -6.18% to $ 30.59 millions, from $ 32.61 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Medical Equipment & Supplies's company achievement, Most analysts pointed out.

Within Medical Equipment & Supplies industry 31 other companies have achieved higher Revenue quarter on quarter growth. While Anika Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 715.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #32
Healthcare Sector #119
Overall #715
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry #32
Healthcare Sector #119
Overall #715
Revenue Q/Q Growth Statistics
High Average Low
60.04 % 4.39 % -33.26 %
(Mar 31 2014)  


ANIK's III. Quarter Q/Q Revenue Comment
In the III. Quarter 2026 Anika Therapeutics Inc disclosed decline in Revenue from the second quarter by -6.18% to $ 30.59 millions, from $ 32.61 millions achived in the previous reporting period.

Although periodic circumstance commonly energize III. Quarter 2026 Revenue, this plainly could not be substantial to rescue Medical Equipment & Supplies's company achievement, Most analysts pointed out.

Within Medical Equipment & Supplies industry 31 other companies have achieved higher Revenue quarter on quarter growth. While Anika Therapeutics Inc 's Revenue growth quarter on quarter, overall rank is 715.


Anika Therapeutics Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)
12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025) 12 Months Ending (Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 121.37
Y / Y Revenue Growth (TTM) 34.57 %
Year on Year Revenue Growth Overall Ranking # 3617
Seqeuential Revenue Change (TTM) 4.52 %
Seq. Revenue Growth (TTM) Overall Ranking # 3298


Cumulative Revenue growth Comment
Anika Therapeutics Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 34.57% year on year, to $ 121 millions if the fiscal year would have ended in Jun 30 2026.
Anika Therapeutics Inc 's trailing twelve months Revenue growth was higher than company's average 5.58% and higher than 11.45% growth in Mar 31 2026.
But from twelve months ended Mar 31 2026 rise was beneth at 4.52 % from $116.12 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at5.58%.

In the Healthcare sector 492 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 762 to 3617.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 154
Healthcare Sector # 493
Overall # 3617

Revenue TTM Y/Y Growth Statistics
High Average Low
40.64 %
5.58 %
-51.23 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 154
Sector # 439
S&P 500 # 3298
Cumulative Revenue growth Comment
Anika Therapeutics Inc saw improvement in Revenue growth trend, posting cumulative 12 months Revenue growth of 34.57% year on year, to $ 121 millions if the fiscal year would have ended in Jun 30 2026.
Anika Therapeutics Inc 's trailing twelve months Revenue growth was higher than company's average 5.58% and higher than 11.45% growth in Mar 31 2026.
But from twelve months ended Mar 31 2026 rise was beneth at 4.52 % from $116.12 millions achieved in the period from Mar 31 2026 to Jun 30 2025.
We witness drop-off happening, more obvious observing the usual Q/Q TTM historic rise that is stronger at5.58%.
The momentum is even more impressive from twelve months ended Mar 31 2026 exhibited at 4.52 % increase from $116.12 millions in the period from Mar 31 2026 to Jun 30 2025.

In the Healthcare sector 492 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 762 to 3617.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Equipment & Supplies Industry # 154
Healthcare Sector # 493
Overall # 3617

Revenue TTM Y/Y Growth Statistics
High Average Low
40.64 %
5.58 %
-51.23 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 154
Sector # 439
S&P 500 # 3298




Other Revenue Growth
Medical Equipment & Supplies Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ANIK's Revenue Growth Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue decline for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Abcellera Biologics Inc 18.81%$ 18.805 millions
Schrodinger Inc 18.72%$ 18.715 millions
Procept Biorobotics Corporation18.41%$ 18.414 millions
Supernus Pharmaceuticals inc 18.05%$ 18.047 millions
Harvard Apparatus Regenerative Technology Inc 17.89%$ 17.886 millions
Outset Medical Inc 17.51%$ 17.510 millions
Cv Sciences Inc 17.41%$ 17.410 millions
Alnylam Pharmaceuticals Inc 16.74%$ 16.738 millions
IMPACT BIOMEDICAL INC.16.67%$ 16.667 millions
Rigel Pharmaceuticals Inc16.45%$ 16.452 millions
Si bone inc 16.42%$ 16.424 millions
Ars Pharmaceuticals Inc 16.03%$ 16.027 millions
Atricure Inc 15.84%$ 15.839 millions
American Shared Hospital Services15.76%$ 15.761 millions
Ardelyx inc 15.70%$ 15.704 millions
Novocure Limited15.67%$ 15.666 millions
Penumbra Inc15.64%$ 15.636 millions
Orasure Technologies Inc15.45%$ 15.445 millions
Electromed Inc 15.34%$ 15.342 millions
Irhythm Holdings Inc 15.34%$ 15.339 millions
P3 Health Partners Inc 14.80%$ 14.798 millions
Msa Safety Inc14.72%$ 14.716 millions
Ensign Group Inc14.47%$ 14.471 millions
Abbott Laboratories14.46%$ 14.460 millions
Electrocore Inc 14.40%$ 14.404 millions
Allogene Therapeutics Inc 14.29%$ 14.286 millions
Tandem Diabetes Care Inc 14.26%$ 14.257 millions
Iradimed Corporation14.15%$ 14.154 millions
Apyx Medical Corp14.09%$ 14.093 millions
Incyte Corporation14.00%$ 13.999 millions


About Anika Therapeutics Inc Revenue Growth Rates (ANIK), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Anika Therapeutics Inc (CIK 898437).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001171843-26-007230
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Anika Therapeutics Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.